Archiv
Archiv anzeigen:
bis


Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer

Robert Dreicer, MD, MS, MACP, FASCO reviewing Sternberg CN et al. N Engl J Med 2020 Jun 4, Higano CS. N Engl J Med 2020 Jun 4

Overall survival was prolonged with enzalutamide versus placebo at extended follow-up.


Proton Beam vs. External Beam Radiotherapy for Locally Advanced Esophageal Cancer

David H. Ilson, MD, PhD reviewing Lin SH et al. J Clin Oncol 2020 May 10

Proton beam therapy may reduce toxicity without affecting clinical outcomes.


Nivolumab plus Ipilimumab for Resected Stage IV Melanoma

Sunandana Chandra, MD reviewing Zimmer L et al. Lancet 2020 May 16

Adding ipilimumab to nivolumab prolonged recurrence-free survival but increased the rate of treatment-related adverse effects.


The Risk for Deep Venous Thrombosis in Patients with COVID-19

Fatima Rodriguez, MD, MPH, FACC, FAHA reviewing Zhang L et al. Circulation 2020 May 18, Ren B et al. Circulation 2020 May 15

Two observational studies from Wuhan suggest that COVID-19 infection is linked to a high incidence of lower-extremity DVT.


An Oral Gonadotropin-Releasing Hormone Antagonist for Advanced Prostate Cancer

Robert Dreicer, MD, MS, MACP, FASCO reviewing Shore ND et al. N Engl J Med 2020 May 29

Relugolix was superior to the injectable luteinizing hormone–releasing hormone agonist leuprolide in providing sustained suppression of testosterone.


Chemotherapy for Breast Cancer Patients with High Recurrence Scores

William J. Gradishar, MD reviewing Ma SJ et al. JAMA Netw Open 2020 May 4

Adjuvant chemotherapy was associated with improved overall survival for patients with recurrence scores of 26 or higher.


Immunotherapy plus Chemotherapy for Advanced Urothelial Cancer

Robert Dreicer, MD, MS, MACP, FASCO reviewing Galsky MD et al. Lancet 2020 May 16, Szabados B and Powles T. Lancet 2020 May 16

Adding atezolizumab to platinum-based chemotherapy significantly prolonged progression-free survival.


Selumetinib for Children with Inoperable Plexiform Neurofibromas

Roy E. Strowd, MD reviewing Gross AM et al. N Engl J Med 2020 Apr 9

Most patients had durable response and improved clinical benefit in a phase II study.


Risk for Thrombosis in Patients with Sickle Cell Disease

Brady L. Stein, MD, MHS reviewing Srisuwananukorn A et al. Blood Adv 2020 May 12

Thrombosis is prevalent in sickle cell patients, especially following hospital discharge and in the presence of vascular access, and is potentially influenced by thrombomodulin gene mutations.


Bevacizumab plus Atezolizumab for Advanced Hepatocellular Cancer

David H. Ilson, MD, PhD reviewing Finn RS et al. N Engl J Med 2020 May 14

Survival was significantly prolonged with combination therapy versus conventional therapy with sorafenib.


Archiv
Seite von 93